Business

UK regulator says Pfizer results ‘very encouraging’; wants to assess full data

LONDON (Reuters) – Britain’s medicines regulator said on Wednesday that final late-stage trial results from Pfizer and BioNTech’s COVID-19 vaccine candidate were very encouraging, adding it would need to see the full data before making an assessment of the shot.

Pfizer Inc. will seek emergency U.S. approval for its COVID-19 vaccine within days after final trial resultsshowed its shot had a 95% success rate and no serious side effects, the drugmaker said on Wednesday.

“The results reported by Pfizer today are very encouraging and add to their announcement last week,”
June Raine, Chief Executive of Medicines and Healthcare products Regulatory Agency (MHRA), said in a statement, which did not give a precise timeframe for UK regulatory approval.

Join The European Business Briefing

New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.

Subscribe

“We look forward to receiving the full results of the trials as soon as possible, after which we will
rigorously assess the evidence of safety and effectiveness of the vaccine.”

Nick Staunton

Nick Staunton is the Editor and Chief Executive of European Business Magazine, one of Europe's leading business and geopolitical analysis publications. He writes primarily on European markets, fintech, defence industry consolidation, and the business impact of geopolitical events. Nick has over a decade of experience in digital publishing and holds editorial responsibility for EBM's coverage of European rearmament, the Iran war's economic consequences, and the structural shifts reshaping European capital markets. He is based in the United Kingdom and is also Chief Executive of NST Publishing Ltd, the parent company of European Business Magazine

Leave a Reply

Your email address will not be published. Required fields are marked *